Compounds of formula (I) wherein, R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R4b and R.sup.5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain. ##STR00001##

Compounds of formula (I) wherein, R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R4b and R.sup.5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain. ##STR00001##

A compound, a material for an organic electroluminescent device and an application thereof are disclosed herein. The compound has a structure represented by Formula (1). The compound has a relatively high refractive index and can effectively improve the light extraction efficiency. The external quantum efficiency of the compound makes it suitable for use as a capping layer when used in an organic electroluminescent device. The compound has a relatively high refractive index in the region of visible light (400-750 nm), which is advantageous for improving the light-emitting efficiency. The compound has a relatively large extinction coefficient in the ultraviolet region (less than 400 nm), which is advantageous for absorbing harmful light and protecting eyesight. Meanwhile, a deuterium atom may be introduced into the compound to significantly improve the device lifetime.

A compound, a material for an organic electroluminescent device and an application thereof are disclosed herein. The compound has a structure represented by Formula (1). The compound has a relatively high refractive index and can effectively improve the light extraction efficiency. The external quantum efficiency of the compound makes it suitable for use as a capping layer when used in an organic electroluminescent device. The compound has a relatively high refractive index in the region of visible light (400-750 nm), which is advantageous for improving the light-emitting efficiency. The compound has a relatively large extinction coefficient in the ultraviolet region (less than 400 nm), which is advantageous for absorbing harmful light and protecting eyesight. Meanwhile, a deuterium atom may be introduced into the compound to significantly improve the device lifetime.

There are described compounds of formula (I): (I) and their use as a medicament in the treatment of diseases associated with the abnormal or elevated catabolism of tryptophan, such as, cancer, immunosuppression, viral infection, depression, a neurodegenerative disorder, trauma, age-related cataracts, organ transplant rejection, or an autoimmune disorder in a patient.

##STR00001##

The present invention provides new compounds and compositions thereof that release carbon monoxide for the treatment of medical disorders that are responsive to carbon monoxide, for example, inflammatory, pain, and dermatological disorders.

In some embodiments of the invention, inventive compounds (e.g., Formula (I), (IA), (II), and (III), and urolithin derivatives) are disclosed. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

Disclosed is a compound of formula (I): ##STR00001## wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

Disclosed is a compound of formula (I): ##STR00001## wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

Compounds of formula (I) wherein, R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R4b and R.sup.5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain.

##STR00001##